Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions

Kazuya Hosokawa; Tomoko Ohnishi; Hisayo Sameshima; Naoki Miura; Takashi Ito; Takehiko Koide; Ikuro Maruyama

doi:10.1160/TH12-06-0441

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2013; 109(01): 102-111
DOI: 10.1160/TH12-06-0441

Platelets and Blood Cells

Schattauer GmbH

Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions

Kazuya Hosokawa

¹Research Institute, Fujimori Kogyo Co., Ltd., Yokohama, Kanagawa, Japan

³Department of System Biology in Thromboregulation, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan

,

Tomoko Ohnishi

¹Research Institute, Fujimori Kogyo Co., Ltd., Yokohama, Kanagawa, Japan

,

Hisayo Sameshima

¹Research Institute, Fujimori Kogyo Co., Ltd., Yokohama, Kanagawa, Japan

,

Naoki Miura

²Department of Veterinary Medicine, Faculty of Agriculture, Kagoshima University, Kagoshima, Japan

,

Takashi Ito

³Department of System Biology in Thromboregulation, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan

,

Takehiko Koide

³Department of System Biology in Thromboregulation, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan

,

Ikuro Maruyama

³Department of System Biology in Thromboregulation, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan

› Author Affiliations

Abstract

Summary

High residual platelet aggregability and circulating platelet-monocyte aggregates in patients administered aspirin and clopidogrel are associated with ischaemic vascular events. To determine the relevance of these factors with residual thrombogenicity, we measured platelet thrombus formation using a microchip-based flow-chamber system in cardiac patients receiving aspirin and/or clopidogrel, and evaluated its correlation with agonist-inducible platelet aggregation and platelet-monocyte aggregates. Platelet thrombus formation was analysed by measuring flow pressure changes due to the occlusion of micro-capillaries and was quantified by calculating AUC₁₀ (area under the flow pressure curve). The growth and stability of platelet thrombi that formed inside microchips at shear rates of 1000, 1500, and 2000 s^-1 were markedly reduced in patients receiving aspirin and/or thienopyridine compared to healthy controls (n=33). AUC₁₀ values of aspirin therapy patients (n=20) were significantly lower and higher than those of healthy controls and dual antiplatelet therapy patients (n=19), respectively, and showed relatively good correlations with collagen-induced platelet aggregation and platelet-monocyte aggregates at 1000 and 1500 s^-1 (r _s>0.59, p<0.01). In contrast, AUC₁₀ in dual antiplatelet therapy patients was significantly correlated with ADP-induced platelet aggregation at all examined shear rates (r _s>0.59, p<0.01), but did not correlate with collagen-induced aggregation. Aspirin monotherapy patients with high residual platelet thrombogenicity also exhibited significant elevations in both collagen-induced platelet aggregation and platelet-monocyte aggregates. Our results, although preliminary, suggest that residual platelet thrombogenicity in aspirin-treated patients is associated with either collagen-induced platelet aggregation or circulating platelet-monocyte aggregates, but it is predominantly dependent on ADP-induced platelet aggregation in patients receiving dual antiplatelet therapy.

Keywords

Antiplatelet therapy - aspirin - clopidogrel - platelet thrombus - blood flow

Full Text

References

References
1 Yusuf S, Zhao F, Mehta SR. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502. DOI:10.1056/NEJMoa010746.
2 Steinhubl S, Roe MT. Optimizing platelet P2Y12 inhibition for patients undergoing PCI. Cardiovasc Drug Rev 2007; 25: 188-203. DOI:10.1111/j.1527-3466.2007.00013.x.
3 Bonello L, Tantry US, Marcucci R. et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919-933. DOI:10.1016/j.jacc.2010.04.047.
4 Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 2007; 115: 2196-2207. DOI:10.1161/CIRCULATIONAHA.106.675991.
5 Wurtz M, Grove EL. Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance. Curr Pharm Des. 2012; in press
6 Krasopoulos G, Brister SJ, Beattie WS. et al. Aspirin ,,resistance“ and risk of cardiovascular morbidity: systematic review and meta-analysis. Br Med J 2008; 336: 195-198. DOI:10.1136/bmj.39430.529549.BE.
7 Sofi F, Marcucci R, Gori AM. et al. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost 2010; 103: 841-848. DOI:10.1160/TH09-06-0418.
8 Lordkipanidze M, Pharand C, Schampaert E. et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28: 1702-1708. DOI:10.1093/eurheartj/ehm226.
9 Lordkipanidze M, Pharand C, Nguyen TA. et al. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur Heart J 2008; 29: 2877-2885. DOI:10.1093/eurheartj/ehn419.
10 Grove EL, Hvas AM, Johnsen HL. et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010; 103: 1245-1253. DOI:10.1160/TH09-08-0527.
11 Sarma J, Laan CA, Alam S. et al. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 2002; 105: 2166-2171. DOI:10.1161/01.CIR.0000015700.27754.6F.
12 Wang J, Zhang S, Jin Y. et al. Elevated levels of platelet-monocyte aggregates and related circulating biomarkers in patients with acute coronary syndrome. Int J Cardiol 2007; 115: 361-365. DOI:10.1016/j.ijcard.2006.03.019.
13 Yong AS, Pennings GJ, Chang M. et al. Intracoronary shear-related up-regulation of platelet P-selectin and platelet-monocyte aggregation despite the use of aspirin and clopidogrel. Blood 2011; 117: 11-20. DOI:10.1182/blood-2010-04-278812.
14 Jackson SP, Nesbitt WS, Westein E. Dynamics of platelet thrombus formation. J Thromb Haemost 2009; 07 (Suppl. 01) 17-20. DOI:10.1111/j.1538-7836.2009.03401.x.
15 Hosokawa K, Ohnishi T, Fukasawa M. et al. A microchip flow-chamber system for quantitative assessment of the platelet thrombus formation process. Microvasc Res 2012; 83: 154-161. DOI:10.1016/j.mvr.2011.11.007.
16 Furman MI, Barnard MR, Krueger LA. et al. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 2001; 38: 1002-1006. DOI:10.1016/S0735-1097(01)01485-1.
17 Ohmori T, Yatomi Y, Nonaka T. et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost 2006; 04: 1271-1278. DOI:10.1111/j.1538-7836.2006.01958.x.
18 Frelinger 3rd AL, Li Y, Linden MD. et al. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterisation. Circulation 2009; 120: 2586-2596. DOI:10.1161/CIRCULATIONAHA.109.900589.
19 Geisler T, Langer H, Wydymus M. et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006; 27: 2420-2425. DOI:10.1093/eurheartj/ehl275.
20 Hochholzer W, Trenk D, Bestehorn HP. et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742-1750. DOI:10.1016/j.jacc.2006.06.065.
21 Price MJ, Endemann S, Gollapudi RR. et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29: 992-1000. DOI:10.1093/eurheartj/ehn046.
22 Marcucci R, Gori AM, Paniccia R. et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009; 119: 237-242. DOI:10.1161/CIRCULATIONAHA.108.812636.
23 Barragan P, Bouvier JL, Roquebert PO. et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003; 59: 295-302. DOI:10.1002/ccd.10497.
24 Mega JL, Close SL, Wiviott SD. et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362. DOI:10.1056/NEJMoa0809171.
25 Simon T, Verstuyft C, Mary-Krause M. et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-375. DOI:10.1056/NEJMoa0808227.
26 Bouman HJ, Harmsze AM, van Werkum JW. et al. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. Heart 2011; 97: 1239-1244. DOI:10.1136/hrt.2010.220509.
27 Mendolicchio GL, Zavalloni D, Bacci M. et al. Variable effect of P2Y12 inhibition on platelet thrombus volume in flowing blood. J Thromb Haemost 2011; 09: 373-382. DOI:10.1111/j.1538-7836.2010.04144.x.
28 Uchiyama S, Yamazaki M, Maruyama S. et al. Shear-induced platelet aggregation in cerebral ischaemia. Stroke 1994; 25: 1547-1551. DOI:10.1161/01.STR.25.8.1547.
29 Goto S, Tamura N, Sakakibara M. et al. Effects of ticlopidine on von Willebrand factor-mediated shear-induced platelet activation and aggregation. Platelets 2001; 12: 406-414. DOI:10.1080/09537100120078377.
30 Sadler JE. von Willebrand factor: two sides of a coin. J Thromb Haemost 2005; 03: 1702-1709. DOI:10.1111/j.1538-7836.2005.01369.x.
31 Hosokawa K, Ohnishi T, Kondo T. et al. A novel automated microchip flow-chamber system to quantitatively evaluate thrombus formation and antithrombotic agents under blood flow conditions. J Thromb Haemost 2011; 09: 2029-2037. DOI:10.1111/j.1538-7836.2011.04464.x.
32 Ogawa S, Szlam F, Ohnishi T. et al. A comparative study of prothrombin complex concentrates and fresh-frozen plasma for warfarin reversal under static and flow conditions. Thromb Haemost 2011; 106: 1215-1223. DOI:10.1160/TH11-04-0240.

Supplementary Material

Online Supplementary Material (PDF)